// App-Quantinova.ai

: TIME FROM RANDOMIZATION TO FIRST SUBSEQUENT INDUCTION/SALVAGE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN IN THE PHASE 3 INO-VATE TRIAL

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Matthias Stelljes

  • Anjali Advani

  • Daniel J DeAngelo

  • Tao Wang

  • Alexander Neuhof

  • Erik Vandendries

  • Hagop Kantarjian

Medical Centers

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Universitatsklinikum Munster, Munster, Germany

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Pfizer Groton CT United States

  • Pfizer Pharma GmbH, Berlin, Germany

  • Pfizer Inc,Cambridge,United States

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved